March 4, 2010
The investigational Alzheimer’s disease drug dimebon failed in the pivotal CONNECTION trial of patients with mild-to-moderate disease, the drug’s makers announced today. Latrepirdine did not result in significant gains on any of the five efficacy endpoints versus placebo after six months of treatment, according to Medivation and Pfizer, who have a partnership to develop the […]
Tags: Alzheimer's drug, dimebon, Dr. Ron Petersen